Objectives: To review the immunogenicity, safety and efficacy of inactivated and attenuated trivalent influenza vaccines in children.
Introduction
The influenza virus is the etiologic agent of the flu, causing annual epidemics which are associated with excessive hospitalizations and mortality, particularly among the elderly and those suffering from underlying conditions, such as cardiopulmonary and metabolic diseases and immunodeficiencies. 1 Prevention of infection by the influenza virus by means of vaccination is recommended for all of these populations and their contacts and also anyone who does not wish to catch the flu. 2 Recently, the Advisory Committee on Immunization Practices (ACIP), in the USA, 2 and the American Academy of Pediatrics 3,4 recommended routine influenza vaccination for children aged 6 to 23 months, considering this age group to be at high risk of increased severity of infection by the influenza virus. This recommendation was based on epidemiological surveys that demonstrated that children in this age group exhibit hospitalization rates that are greater than or equal to those observed in other high risk groups. 5, 6 Furthermore, use of the inactivated influenza vaccine with children at this age has been proven to be safe and to have acceptable efficacy, backing up the recommendation. 7 The objective of this review is to use medical literature and Brazilian epidemiological data to briefly characterize the impact of the flu and the benefits, immunogenicity, safety and efficacy of vaccinating healthy children against the influenza virus, especially in the 6 to 23 months age group.
Database searches were run on MEDLINE, LILACS and the Cochrane Library and specialists were consulted on the following themes: influenza, influenza vaccine, infants, vaccine efficacy and adverse events. The most relevant articles were selected from those that reported on randomized, double-blind and controlled clinical trials, in addition to national or international epidemiological population-based incidence studies.
Biology and epidemiology of the influenza virus
The influenza virus is an orthomyxovirus with an envelope and single-strand segmented RNA. It has two surface glycoproteins, which play important roles in its antigenicity and pathogenicity, named hemagglutinin (HA) and neuraminidase (NA). 9 Influenza viruses are classified into one of three subtypes, A, B or C, with the first of these being associated with the greatest antigenic variation in HA and NA. 9 Three HA (H1, H2 and H3) and two NA (N1 and N2) variants are associated with infections in human beings, 9 although other variants, such as H5N1, that are typically observed in other species, have caused infections in humans who have had contact with poultry. 10, 11 Influenza viruses cause annual epidemics that are associated with significant morbidity and mortality and have a major impact on public health, with around 20 thousand deaths/year and 140 thousand hospitalizations/ year, on average, in the USA. 12, 13 The populations at greatest risk present more severe infections by the influenza virus and excessive levels of pneumonia, mortality and hospital admissions, particularly among the elderly, cardiopulmonary patients and people with immunodeficiencies. 12, 13 In temperate countries and in the South and Southeast of Brazil, influenza virus epidemics typically occur during the winter months. 14, 15 In regions with tropical climates, however, they can happen at any time of year, sometimes more than once a year, and may be associated with rainy seasons. 16 The circulation of the influenza virus is global and annual epidemics and pandemics are associated with population immunity to the subtype in circulation, with the epidemics being associated with small variations within a subtype (antigenic drift) and pandemics with major antigenic variation (antigenic shift). 1 
Impact of the influenza virus on children
Glezen et al. 17 described the typical progression of an influenza epidemic, with an average duration of 6 to 8 weeks, starting among schoolchildren and later passing to economically active adults. The role of children in the spread of these viruses is clear, having also been reported in more recent epidemiological studies. [18] [19] [20] [21] Children do not only disseminate the influenza virus, but can also present significant morbidity associated with flu infections, with less typical and sometimes more severe clinical manifestations. 22 Encephalitis cases caused by the influenza virus have been described in children. 23, 24 In the USA, 121 deaths were associated with influenza infections in patients less than 18 years old, with just 26% of these having risk factors for greater severity. 25, 26 The fact that hospital admissions among children under 5 years of age increase in frequency during influenza epidemics has been known for several years. 27, 28 Nevertheless, since the respiratory syncytial virus (RSV)
is one of the principal agents of hospitalization in children less than 1 year old with lower respiratory tract infections, and since RSV exhibits similar seasonality to the influenza virus, the real importance of the influenza virus was initially undervalued in this age group. 28, 29 Later, Neuzil et al. 5 and Izurieta et al. 6 demonstrated that the influenza virus was also associated with hospitalizations and morbidity to as significant an extent as RSV. These authors were able to characterize the varying periods of predominance of each agent and the rates of hospitalization associated with each one. Since then other studies have confirmed these authors findings, demonstrating the true impact of influenza virus infections in children, associated with increased severity, increase in the number of medical consultations, use of antibiotics, parents absenteeism from work and the appearance of secondary cases. [19] [20] [21] 30 Acute respiratory infections are the most important cause of mortality in children under 5 years in developing countries. 31 Despite bacterial etiology being considered more associated with mortality, viruses present very significant frequency and are associated with secondary infections. 16, 32 Kim et al. 33 demonstrated an association between influenza epidemics and an increased number of identifications of pneumococcus in invasive infections, which was confirmed experimentally by Peltola et al. 34 and
by OBrien et al. 35 in case control studies of pneumococcal pneumonia. The experimental efficacy of vaccination and of treating influenza with antivirals for preventing mortality in mice by invasive pneumococcal infection were also recently confirmed. 36, 37 The impact of the influenza virus on children in Brazil
Currently, the epidemiology of the influenza virus is well known in Brazil and its seasonality has been well characterized, with outbreaks taking place in the winter months in the South and Southeast regions. 1 Brazil has referral centers for the diagnosis and identification of In Rio de Janeiro (Rio de Janeiro state), Sutmoller et al. 43 and Nascimento et al. 44 detected the influenza virus in 10 and 6.7% of children under 5 years old with acute respiratory infections (ARI), respectively. In Porto Alegre (Rio Grande do Sul state), Stralioto et al. 45 detected the virus in 1.7% of children from 0 to 5 years old with ARI seen at an emergency room. In a longitudinal study of children with respiratory symptoms in the city of Fortaleza (Ceará state) Arruda et al. 46 detected the influenza virus in 5.7% of patients with upper airway infections.
Even without the mass of epidemiological data available on North-America, we can infer that the influenza virus is an important causal agent of ARI in Brazilian children under 5 years old and that it is associated with increased hospital admissions for lower airway infections, with significant morbidity.
Influenza vaccines
The different types of influenza vaccines are listed in Table 1 immunogenicity and safety to other vaccines. 47, 48 A nasal formulation was used in a clinical trial with children and later abandoned due to a link with facial paralysis. 48, 49 Recently, a trivalent, live, attenuated, cold-adapted influenza vaccine (LAIV) was licensed in the USA. 50 An attenuated vaccine had been previously used in the nowextinct USSR and had been studied in the USA since the 1960s, being now revisited with nasal administration. 51, 52 The vaccine that is currently licensed in the USA must be stored frozen at -15 ºC and was approved for use with healthy children and adults from 5 to 49 years of age. 50 The attenuated influenza vaccine was shown to be safe, immunogenic and effective, although there are doubts about its safety in small children, the elderly and patients with immunosuppression, despite having been tested in clinical trials with these populations. [53] [54] [55] This vaccine can induce systemic humoral and mucosal immunoresponse, in addition to cellular immunoresponse, being capable of inducing cross-protection against other influenza strains. 56 A liquid formulation that does not require freezing is currently in phase III clinical trials. 57 Influenza vaccines are modified annually, based on which could lead to increased influenza vaccine production capacity. [58] [59] [60] 
Safety of the influenza vaccines in children
The safety of trivalent inactivated and attenuated influenza vaccines has been tested in clinical trials and reviews of databases on vaccine-related adverse events.
Neuzil et al. 7 reviewed adverse reactions at a clinical research center in the USA over a 5-year period in 277 children aged 1 to 16 years who were given 635 doses of vaccine. No severe reactions were observed and local reactions occurred in 6 to 14% of those who were vaccinated. In another randomized, double-blind, placebo controlled multicenter study of 2,032 patients with asthma, 712 of whom were aged 3 to 18 years, no asthma exacerbations were observed among those vaccinated up to 2 weeks after vaccination. 61 Guillian-Barré syndrome has not been linked with the inactivated vaccine in children, but the relatively small number of patients in the studies compromise their power for detecting extremely rare events. 7 
Immunogenicity
The immunogenicity of the inactivated influenza vaccine is directly proportional to age. 7 In children under 6 years of age, approximately 40 to 80% exhibit seroconversion after a single dose of vaccine, while for children over 6 years the rate of seroconversion rises to 70 to 100%. 65, 66 More than 50% of children under 3 years old and around 30% of children up to 9 years old are seronegative for the influenza virus. 67 This fact results in the recommendation to give two doses of vaccine to the 6 months to 9 years age group the first year of vaccination, with just one dose being required annually thereafter. 68 Recently, Englund et al. 69 studied the immunogenicity of the inactivated influenza vaccine in children from 6 to 23 months. These authors assessed the immunogenicity of the classic course of two doses with a 1 month interval and compared it with a course using a 6 month interval between doses, using vaccines with the same antigenic composition. Overall, rates of seroconversion were from 58 to 88%, varying for each of the three antigens, and no differences were observed between the two vaccine courses. These results support the idea that the reduced response to the influenza vaccine in children is associated with the need for previous contact with the antigen and thus could favor the immunization of small children with doses left over from previous years with the second dose being given during the annual vaccination season.
T h e a t t e n u a t e d i n f l u e n z a v a c c i n e e x h i b i t s seroconversion rates of 61 to 96% measured by hemagglutination inhibition titers that are elevated four times or more. 52 In another study the rates of seroconversion were 90, 50 and 16%, varying according to influenza subtype. 70 In truth, there is no exclusive measure of seroconversion, since the vaccine also induces mucosal and cellular immunity. 50 
Efficacy of the influenza vaccine in children
The results of clinical trials investigating the efficacy of the inactivated influenza vaccine vary greatly, depending on the primary objective of each study. 8 In general, efficacy against confirmed influenza virus infection varies from 31 to 91% and is not uniform for the subtypes. Jefferson et al. 80 reviewed the efficacy of the attenuated vaccine in healthy children, reporting it at 79%. These authors report that the efficacy of the inactivated vaccine is 65%. The effectiveness of vaccination was 38% for the attenuated vaccine and 28% for the inactivated vaccine, in both cases for children older than 2 years. Efficacy for children younger than 2 years was not studied systematically, with the exception of the investigations into AMO episodes mentioned above.
Population-based studies of the impact of influenza vaccination with the inactivated vaccine in schoolchildren showed control of influenza epidemics with reductions in the total number of cases and in viral dissemination. 81 The same result was recently reported for the attenuated vaccine by Piedra et. al., 82 who observed reductions in the number of medical consultations in unvaccinated people when vaccination coverage reached 25% of schoolchildren. In Japan, the national program for influenza vaccination of schoolchildren was associated with reduced mortality by influenza among the elderly. 83 Universal influenza vaccination is currently under debate as a more effective alternative for preventing the disease. 68, 84 Final comments Acute respiratory infections are a worldwide public health problem, with significant impact on morbidity and mortality in children under 5 years of age and in other high-risk populations. 31 Vaccination is an effective measure for controlling these diseases, as has been observed for measles and invasive Haemophilus influenzae type B infections. 85 Vaccination against influenza has surfaced as a new weapon in the fight to prevent ARI in children. With the epidemiological data that are currently available on the impact of this agent on the pediatric age group, we can infer that the benefits of vaccination would be reductions in morbidity, observed through the reductions in number of hospital admissions, medical consultations and antibiotic prescriptions for healthy children during influenza epidemics. 84 Without doubt, a major impact would be felt from an influenza immunization program that covered all schoolchildren, however, the vaccination of small groups, particularly through programs in partnership with businesses or health insurance plans, would be a good start for assessing the impact of influenza vaccination. 68, 84 Secondary benefits, such as reductions in parents absenteeism from work, reduced circulation of influenza viruses at daycare centers, and even reductions in secondary cases among family members would be another impact of vaccination against influenza in children, which would make vaccination more cost-effective. Therefore, the current recommendation on influenza vaccination for children is that pediatricians should indicate the vaccination of all children over 6 months old with risk factors and for all children aged 6 to 23 months.
For all other age groups, it is suggested that the vaccine be offered, emphasizing the benefits of vaccination for the prevention of influenza infections and their complications.
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